Systematic review and meta-analysis evaluating the incidence and comparative cardiotoxicity risk of newer HER2-directed therapies (such as antibody-drug conjugates and tyrosine kinase inhibitors) in breast cancer patients.
The paper text was not provided beyond the title and metadata, so specific results, sample sizes, and limitations cannot be extracted.
Explore related topics
